Citations

Showing 10 of 108135 citations.

Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis
Parkman, Henry P. , Natta, Mark L. Van , Grover, Madhusudan , McCallum, Richard W. , Malik, Zubair , Koch, Kenneth L. , Sarosiek, Irene , Kuo, Braden , Shulman, Robert J. , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , Makol, Ashima , Grover, Madhusudan , McCallum, Richard W , Koch, Kenneth L , Sarosiek, Irene , Kuo, Braden , Shulman, Robert , Abell, T L , Parkman, H P , Abell, Thomas L.

Mayo Clinic

Neurogastroenterology & Motility | October 1, 2021 | Volume: 34 | Issue: 5 | Pages: No page available

10.1111/nmo.14270 | PMID 34595805 Get It

AbstractBackgroundAutoimmunity may play a role in the pathogenesis of gastroparesis in a subset of patients. Antinuclear antibody (ANA) testing is often used to screen for autoimmune disorders.Aims1) Determine prevalence of a positive ANA in patients with gastroparesis; 2) Describe characteristics of idiopathic gastroparesis patients with positive ANA.MethodsPatients were assessed with gastric emptying scintigraphy (GES), symptom assessment via Patient Assessment of Upper GI Symptoms [PAGI‐SYM], and blood tests—ANA, erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP).ResultsPositive ANA was seen in 148 of 893 (17%) patients with gastroparesis, being similar in idiopathic (16% of 536 patients), T1DM (16% of 162), T2DM (18% of 147), and postfundoplication (19% of 48 patients) gastroparesis. Among 536 patients with idiopathic gastroparesis, ANA titer 1:40–1:80 was seen in 33 (6%) patients, 1:160–1:320 in 36 (7%) patients, and ≥1:640 in 17 (3%) patients. Increasing ANA titer was associated with female gender (p = 0.05), Hispanic ethnicity (p = 0.02), comorbid rheumatoid arthritis (p = 0.02), systemic sclerosis (p = 0.004), and elevated ESR (p = 0.007). ANA positivity was associated with lower total GCSI (p = 0.007) and lower nausea/vomiting subscale (p = 0.0005), but not related to gastric emptying.ConclusionsThe prevalence of a positive ANA in patients with gastroparesis was high at ~17% and did not differ significantly based on etiology. In idiopathic patients, ANA positivity was associated with rheumatoid arthritis, systemic sclerosis, and elevated ESR. ANA‐positive gastroparesis represents a subset who often have other autoimmune symptoms or disorders, but less severe nausea and vomiting.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff, Craig L. , Lewis, Karl D. , Andtbacka, Robert Hans Ingemar, Hyngstrom, John , Milhem, Mohammed , Bowles, Tawnya L. , Hamid, Omid , Hernandez‐Aya, Leonel F. , Claveau, Joël, Jang, Sekwon, Philips, Prejesh, Holtan, Shernan G. , Shaheen, Montaser , Curti, Brendan D. , Schmidt, William, Butler, Marcus O. , Paramo, Juan, Lutzky, Jose , Padmanabhan, Arvinda, Thomas, Sajeve , Milton, Daniel T., Pecora, Andrew L. , Sato, Takami , Hsueh, Eddy C. , Badarinath, Suprith, Keech, John A., Kalmadi, Sujith, Kumar, Pallavi , Weber, Robert, Levine, Edward A. , Berger, Adam C. , Bar, Anna, Travers, Jeffrey B. , Mihalcioiu, Catalin , Gastman, Brian , Beitsch, Peter D. , Rapisuwon, Suthee , McCarron, Edward C. , Gupta, Vinay , Behl, Deepti , Blumenstein, Brent A. , Peterkin, Joanna, Curti, Brendan , Lutzky, Jose , Rapisuwon, Suthee , Milhem, Mohammed M , Butler, Marcus O , Levine, Edward A , Holtan, Shernan , Markovic, Svetomir N. , Paramo, Juan, Milton, Daniel, Beck, J. Thaddeus , Glaspy, John A.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 1, 2021 | Volume: 9 | Issue: 10 | Pages: e003272

10.1136/jitc-2021-003272 | PMID 34599031 Get It

Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.
Primary Tumors of the Pituitary Gland: Radiologic-Pathologic Correlation
Shih, Robert , Schroeder, Jason W. , Koeller, Kelly K. , Shih, Robert Y

Mayo Clinic

RadioGraphics | October 1, 2021 | Volume: 41 | Issue: 7 | Pages: 2029-2046

10.1148/rg.2021200203 | PMID 34597177 Get It

Translational Applications of Linear and Circular Long Noncoding RNAs in Endometriosis
Wang, Xiyin , Hawkins, Shannon M. , Hawkins, Shannon M , Parodi, Luca

Mayo Clinic

International Journal of Molecular Sciences | October 1, 2021 | Volume: 22 | Issue: 19 | Pages: 10626

10.3390/ijms221910626 | PMID 34638965 Get It

Endometriosis is a chronic gynecologic disease that negatively affects the quality of life of many women. Unfortunately, endometriosis does not have a cure. The current medical treatments involve hormonal manipulation with unwanted side effects and high recurrence rates after stopping the medication. Sadly, a definitive diagnosis for endometriosis requires invasive surgical procedures, with the risk of complications, additional surgeries in the future, and a high rate of recurrence. Both improved therapies and noninvasive diagnostic tests are needed. The unique molecular features of endometriosis have been studied at the coding gene level. While the molecular components of endometriosis at the small RNA level have been studied extensively, other noncoding RNAs, such as long intergenic noncoding RNAs and the more recently discovered subset of long noncoding RNAs called circular RNAs, have been studied more limitedly. This review describes the molecular formation of long noncoding and the unique circumstances of the formation of circular long noncoding RNAs, their expression and function in endometriosis, and promising preclinical studies. Continued translational research on long noncoding RNAs, including the more stable circular long noncoding RNAs, may lead to improved therapeutic and diagnostic opportunities.
Nuclear Dynamics and Chromatin Structure: Implications for Pancreatic Cancer
Flores, Luis F. , Tader, Brooke R , Tolosa, Ezequiel J. , Sigafoos, Ashley N. , Marks, David L. , Fernández-Zapico, Martín E. , Fernandez-Zapico, Martin E

Mayo Clinic

Cells | October 1, 2021 | Volume: 10 | Issue: 10 | Pages: 2624

10.3390/cells10102624 | PMID 34685604 Get It

Changes in nuclear shape have been extensively associated with the dynamics and functionality of cancer cells. In most normal cells, nuclei have a regular ellipsoid shape and minimal variation in nuclear size; however, an irregular nuclear contour and abnormal nuclear size is often observed in cancer, including pancreatic cancer. Furthermore, alterations in nuclear morphology have become the ‘gold standard’ for tumor staging and grading. Beyond the utility of altered nuclear morphology as a diagnostic tool in cancer, the implications of altered nuclear structure for the biology and behavior of cancer cells are profound as changes in nuclear morphology could impact cellular responses to physical strain, adaptation during migration, chromatin organization, and gene expression. Here, we aim to highlight and discuss the factors that regulate nuclear dynamics and their implications for pancreatic cancer biology.
Compensatory and Lifestyle-Based Brain Health Program for Subjective Cognitive Decline: Self-Implementation versus Coaching
Liou, Harris , Stonnington, Cynthia M. , Buckner‐Petty, Skye , Shah, Amit A, Buckner-Petty, Skye A, Shah, Amit , Locke, Dona E.C.

Mayo Clinic

Brain Sciences | October 1, 2021 | Volume: 11 | Issue: 10 | Pages: 1306

10.3390/brainsci11101306 | PMID 34679371 Get It

Although recent studies have explored the potential of multidomain brain health programs, there is a dearth of literature on operationalizing this research to create a clinical treatment program specifically for subjective cognitive decline (SCD). Patients seen by geriatricians in primary care and by behavioral neurology services at our institution presenting with SCD were recruited via a patient-appropriate flyer. After all participants had a 1-h brain health consultation with a neuropsychologist and were provided with program materials, they were randomized to attend a 10-week intervention designed to support program implementation (N = 10) or the control group of implementing the program on their own (N = 11). The program included (1) a calendar-based executive and memory support system for compensatory training and (2) training in healthy lifestyle. There were no significant differences between groups for any outcomes. Participants across both groups showed significant improvements with moderate effect sizes in compensatory strategy use, anxiety symptoms, and daily functioning, which were sustained through 6-month follow-up. They also increased physical activity by the end of the intervention period but did not sustain this through 6-month follow-up. Our pilot study demonstrates preliminary feasibility of a cognitive compensatory and lifestyle-based brain health program. Additional research is recommended to further develop two potentially scalable implementation strategies—coaching and self-implementation after brief consultation.
Association of 3 CDC opioid prescription guidelines for chronic pain and 2 payer pharmacy coverage changes on opioid initiation practices
Togun, Adeniyi , Karaca‐Mandic, Pinar , Wurtz, Rebecca , Jeffrey, Molly M, Beebe, Timothy J.

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | October 1, 2021 | Volume: 27 | Issue: 10 | Pages: 1352-1364

10.18553/jmcp.2021.27.10.1352 | PMID 34595944 Get It

Cascade of Care in the Management of Latent Tuberculosis Infection in the United States: A Lot to Improve and to Scale Up
Wilson, John , Kissner, Dana G., Escalante, Patricio

Mayo Clinic

Annals of the American Thoracic Society | October 1, 2021 | Volume: 18 | Issue: 10 | Pages: 1620-1621

10.1513/annalsats.202106-722ed | PMID 34596496 Get It

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Loehr, Andrea , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Vogelzang, Nicholas J. , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Hussain, Arif , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim , Ryan, Charles J , Daugaard, Gedske , Heidenreich, Axel , Sternberg, Cora N , Watkins, Simon P , Simmons, Andrew D , Golsorkhi, Tony , Bryce, Alan H , Vogelzang, Nicholas J , McDermott, Ray , Patnaik, Akash , Piulats, Josep M.

Mayo Clinic

Clinical Cancer Research | October 1, 2021 | Volume: 27 | Issue: 24 | Pages: 6677-6686

10.1158/1078-0432.ccr-21-2199 | PMID 34598946 Get It

Abstract Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA+), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report clinical efficacy in patients with BRCA+ mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2. Patients and Methods: Patients had progressed after next-generation androgen receptor–directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. Results: TRITON2 enrolled 115 patients with BRCA+ identified by central plasma (n = 34), central tissue (n = 37), or local (n = 44) testing. Plasma/tissue concordance was determined in 38 patients with paired samples and was 47% in 19 patients with a somatic BRCA alteration. No statistically significant differences were observed between objective and PSA response rates to rucaparib across the 3 assay groups. Patients unable to provide tissue samples and tested solely by plasma assay responded at rates no different from patients identified as BRCA+ by tissue testing. Conclusions: Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA+ mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.
Introduction. Vestibular schwannoma surgery
Link, Michael J. , Barker, Fred G., Samii, Amir, Theodosopoulos, Philip V. , Yang, Isaac

Mayo Clinic

Neurosurgical Focus: Video | October 1, 2021 | Volume: 5 | Issue: 2 | Pages: V1

10.3171/2021.7.focvid21148 Get It